Date: December 09, 2024



#### To, **The Manager**, **BSE Limited Address:** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001.

#### Scrip Code: 540654

#### Subject: Outcome of Board meeting of the Company held today i.e., Monday, December 09, 2024:

# <u>Reference: Outcome of the Board meeting dated November 14, 2024 & Intimation dated December 03, 2024:</u>

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 30 read with Regulation 33 of the Listing Regulations, the Board at its meeting held today i.e. Monday, December 09, 2024, through video Conferencing, inter alia, considered and approved the following:

1) Considered and approved the Un-Audited Consolidated Financial Results along with the Limited Review Report of the Auditors thereon, for the quarter and half-year ended September 30, 2024.

The Board Meeting commenced at 04:30 P.M. and concluded at 06:15 P.M.

Kindly take the same on your records.

#### FOR GLOBALSPACE TECHNOLOGIES LIMITED

Krishna Murari Singh Managing Director DIN: 03160366 Place: Mumbai

## **Chartered Accountants**

Independent Auditor's Limited Review Report on Consolidated Unaudited Half year and Quarterly Financial Results and year to date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

#### To, The Board of Directors, Globalspace Technologies Limited

1. We have reviewed the unaudited financial results of GlobalSpace Technologies Limited (the 'Company') for the half year and quarter ended September 30, 2024 (the 'Statement') attached herewith being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 which has been initialed by us for identification purposes.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind As 34) prescribed under section 133 of the Companies Act 2013 and Rule 3 of Companies (Indian Accounting Standards) Rules 2015 read with SEBI Circular No.CIR/CFD/FAC/621 2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33

Of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement, except for the following:

- During the Quarter the Consolidated Revenue of the Company is Rs. 1157.36 lakhs out of which Rs. 342.75 Lacs and during the half yearly the Consolidated Revenue of the Company is Rs. 2160.47 lakhs out of which Rs. 653.12 Lacs were related to New Subsidiary Company Innopharma Healthcare Private Limited.
- The controlling stake of 51% in the subsidiary company Innopharma Healthcare Private Limited has been acquired on 17th June 2024 and hence no comparative quarter/ half year/ year except for the once prepared after acquisition i.e. quarter needed 30th June 2024 and quarter and half year ended 30th September 2024.

<sup>1027,</sup> Hubtown Solaris, N.S. Phadke Marg, Near TeliGali Signal, Andheri-East, Mumbai-400069, Phone No. 022-67410769, Email: <u>mumbai.blsc@gmail.com</u>, <u>sahil.kothari1@gmail.com</u>

## **Chartered Accountants**

- The cash flow statement has not been prepared as the half year ended 30th September 2024 is the first statement drafted post acquisition.
- The accounts of the subsidiary have been not been reviewed by us and we have relied upon the financial statement as drafted by the auditor of the subsidiary.
- During the Last quarter the company has Capital Loss of INR 275.65 Lacs due to loss on sale of the Kolkata Property has been shown in Exceptional items.
- > The inventory register maintained is not updated with details for quantity inwards and quantity outwards, movement of the inventory.
- Equity Commitment towards M/s Miljon Medi App LLP of Rs. 1,144.33 lakhs is pending for share allotment in the books as on 30.06.2024.

For Bansilal Shah & Co. Chartered Accountants FRN No: 000384W

Dhruv Shah Partner Membership Number 223609 Place: Mumbai Date: 9<sup>th</sup> December 2024 UDIN: 24223609BKEZZI1674



#### GlobalSpace Technologies Limited Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710 CIN: L64201MH2010PLC211219 Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in Extract of Un-Audited Consolidated Financial Results for the quarter ended September 30, 2024

Half year ended 30-Sep-24 30-Sep-23 Sr.No Particulars Amount Amount Т ASSETS 1 Non-current assets 424.32 1,142.27 (a) Property, plant and equipment (b) Intangible assets 671.11 836.55 71.25 (c) Intangible assets under development 292.21 (d) Right to use 0.25 (e) Financial assets (i) Investments 1,245.08 1,245.08 (ii) Other non current financial 747.57 824.45 (ii) Deferred tax assets (net) 34.82 (f) Other non current assets 2.19 Total of non current assets 4,042.71 3,494.42 2 Current Assets (a) Inventories 577.34 584.41 (b) Financial assets (i) Trade receivables 233.74 1,252.42 (ii) Cash and cash equivalents 0.64 0.62 364.83 54.38 (iii) Loans (vi) Others financial assets (c) Current Tax Assets (Net) 143.62 33.60 (d) Other current assets 1,913.85 1,268.14 3,193.57 **Total Current Assets** 3,234.03 Total assets 6,728.45 7,236.28 EQUITY AND LIABILITIES Ш 1 Equity (a) Equity share capital 3,436.98 1,145.66 2,494.67 (b ) Other equity 1.950.31 (c) Non Controlling Interest 60.65 (d) Capital reserve on Consolidation 10.84 Total equity 5,458.77 3,640.33 2 Liabilities Non-current liabilities (a) Financial liabilities 155.49 2,168.93 (i) Borrowings (b) Provisions 20.88 17.23 (c) Deferred tax liabilities (net) 31.07 Total of non current liabilities 176.37 2,217.24 ii Current Liabilities (a) Financial Liabilities (i) Borrowings 806.85 1,142.10 (ii) Trade payables Total outstanding dues of micro enterprises and small enterprises 78.89 Total outstanding dues of creditors other than micro enterprises 99.31 22.03 and small enterprises (iii) Other financial liabilities (b) Other financial liabilities 68.21 154.52 (c) Other current liabilities 39.77 48.39 (d) Provisions 11.67 0.28 **Total liabilities** 1,093.31 1,378.72 Total equity and liabilities 6,728.45 7,236.28

For Bansilal Shah & Co Chartered Accountants FRN No : 000384W



Partner Membership No : 223609 UDIN: 24223609BKEZZI1674 Place: Mumbai Date : 09.12.2024 For Globalspace Technologies Limited

Krishna Murari Singh Chairman and Managing Director DIN : 03160366

Place: Navi Mumbai Date : 09.12.2024



### **GlobalSpace Technologies Limited**

Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710

CIN: L64201MH2010PLC211219

Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in

Extract of Un-Audited Standalone and Consolidated Financial Results for the quarter ended September 30, 2024

**Rs in lacs** 

Sr. No.	Particulars	Rs in lacs Consolidated		
		Quarter Ended		Half year ended
		30-Sep-24	30-Jun-24	30-Sep-24
	Ī	(Un-Audited)	(Un-Audited)	(Un-Audited)
1	INCOME			
a.	Revenue from operation	1,157.36	1,003.11	2,160.47
b.	Other Income	2.06		2.06
	Total Income	1,159.42	1,003.11	2,162.53
2	Expenses			-
	Cost of materials Consumed	646.35	557.69	1,204.04
	Changes in Inventory of Stock in trade			0.30
	Employee Benefits Expenses	281.88	268.81	550.69
	Depreciation and Amortisation Expenses	52.99	56.09	109.08
	Finance Cost	25.13	30.91	56.03
	Other Expenses	125.33	134.32	259.64
	Total Expenses	1,131.68	1,047.81	2,179.78
3	Profit/Loss Before Exceptional Items and tax(1-2)	27.74	-44.70	-17.25
	Exceptional Items	-0.00	-275.65	-275.65
	Finance Cost			
4	Profit/(Loss)before tax	27.74	-320.35	-292.90
	Tax Expense			-
	Current Tax	0.81	-	0.81
	Deferred Tax	20.99	-62.89	-41.90
	Total Tax Expenses	21.80	-62.89	-41.09
6	Net Profit/(Loss) after tax(4-5)	5.94	-257.46	-251.81
7	Other Comprehensive Income	-		
	Items that will not be reclassified into Profit or Loss	-0.50	-	-0.50
	Total Comprehensive Income		-	-
8	Total Comprehensive Income for the year (after			
	tax) (5+6)	5.44	-257.46	-252.31
10	Less: Share of Non Controlling Interest	1.24		1.24
11	Total Comprehensive Income for the year (after tax) for controlling interest (5+6)	4.20	-257.46	-253.55
12	Paid-up Equity Share Capital (Face Value of Re. 10	4.20	237.40	
	/- each)	1,145.66	1,145.66	1,145.66
13	Other Equity	1,951.84	1,946.40	1,951.84
14	Earnings per Equity Share (of Rs. 10/- each)			
	Basic	0.05	-2.25	-2.20
	Diluted	0.05	-2.25	-2.20

Notes:

1 The above results were reviewed by the Audit Committee and taken on record where the board of Directors at their meeting held on 9th December 2024.

2 The Statutory auditors have conducted the audit of the financial statements auditors ressed an un qualified audit opinion.



- 3 The format for Un-audited quarterly / half yearly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- 4 The financial results of the Company and its subsidiaries have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016. The subsidiary has adopted Ind AS from 1st April, 2023, and accordingly, these financial results (Including for all the periods presented in accordance with Ind AS 101 - First-time Adoption of Indian Accounting Standards) have been prepared.
- 5 The controlling stake of 51% in the subsidiary company Innopharma Healthcare Private Limited has been acquired on 17th June 2024 and hence no comparative quarter/half year/year except for the once prepared after acquisition i.e. quarter needed 30th June 2024 and quarter and half year ended 30th September 2024.
- 6 The cash flow statement has not been prepared as the half year ended 30th September 2024 is the first statement drafted post acquisition.
- 7 The accounts of the subsidiary have been not been reviewed by us and we have relied upon the financial statement as drafted by the auditor of the subsidiary.
- 8 Previous period figures have been re-grouped / re-classified wherever necessary.

For Bansilal Shah & Co Chartered Accountants FRN No : 000384W



CA Dhruv Shah Partner Membership No : 223609 UDIN: 24223609BKEZZI1674 Place: Mumbai Date : 09.12.2024

#### For Globalspace Technologies Limited

Krishna Murari Singh Chairman and Managing Director DIN : 03160366

Place: Navi Mumbai Date : 09.12.2024